1h Free Analyst Time
The hyperparathyroidism market is forecasted to grow by USD 486.7 million during 2023-2028, accelerating at a CAGR of 7.1% during the forecast period. The report on the hyperparathyroidism market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rise in thyroid treatment awareness programs, growing focus on emerging economies, and increasing drug discovery.
The hyperparathyroidism market is segmented as below:
By Disease Type
- Secondary hyperparathyroidism
- Primary hyperparathyroidism
- Tertiary hyperparathyroidism
By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the hyperparathyroidism market covers the following areas:
- Hyperparathyroidism Market sizing
- Hyperparathyroidism Market forecast
- Hyperparathyroidism Market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Disease Type
9 Market Segmentation by Distribution Channel
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global hyperparathyroidism market: AbbVie Inc., Accord Healthcare Ltd., AdvaCare Pharma, Alkem Laboratories Ltd., Amgen Inc., Ascendis Pharma AS, Aurobindo Pharma Ltd., Biocon Ltd., Cipla Inc., Dr Reddys Laboratories Ltd., EA Pharma Co. Ltd., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Lupin Ltd., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increasing inorganic growth strategies among vendors."
According to the report, one of the major drivers for this market is the rise in thyroid treatment awareness programs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Accord Healthcare Ltd.
- AdvaCare Pharma
- Alkem Laboratories Ltd.
- Amgen Inc.
- Ascendis Pharma AS
- Aurobindo Pharma Ltd.
- Biocon Ltd.
- Cipla Inc.
- Dr Reddys Laboratories Ltd.
- EA Pharma Co. Ltd.
- F. Hoffmann La Roche Ltd.
- Fresenius SE and Co. KGaA
- Lupin Ltd.
- Sanofi SA
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Zydus Lifesciences Ltd.
